We are live on ! Find out more
ACIU icon

AC Immune
ACIU

22 hedge funds and large institutions have $143M invested in AC Immune in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

47% more funds holding

Funds holding: 15 → 22 (+7)

30% more capital invested

Capital invested by funds: $110M → $143M (+$33.2M)

2.51% more ownership

Funds ownership: 17.12% → 19.63% (+2.5%)

Holders
22
Holders Change
+7
Holders Change %
+46.67%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$14.2M
2
TCM
Tekla Capital Management
Massachusetts
+$1.54M
3
Morgan Stanley
Morgan Stanley
New York
+$687K
4
Renaissance Technologies
Renaissance Technologies
New York
+$132K
5
Barclays
Barclays
United Kingdom
+$120K

Top Sellers

Rank Fund Capital Flow
1
BAM
Belpointe Asset Management
Nevada
-$4.12K
2
Wells Fargo
Wells Fargo
California
-$212

ACIU Hedge Fund Activity: Q4 2017 in Review

22 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q4 2017, worth a combined $143M — up 30% from $110M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ACIU positions and 0 closed out — a net gain of 7 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $14.2M. The largest seller was Belpointe Asset Management, cutting an estimated $4.12K.

  • 22 institutional investors held AC Immune (ACIU) as of Q4 2017, up from 15 in Q3 2017.
  • Funds reported $143M of AC Immune stock for Q4 2017, up 30% quarter-over-quarter.
  • 7 funds opened new AC Immune positions in Q4 2017 and 0 closed out, a net change of +7 holders.
  • The largest AC Immune buyer in Q4 2017 was Fidelity Investments, an estimated $14.2M added.
  • The largest AC Immune seller in Q4 2017 was Belpointe Asset Management, an estimated $4.12K sold.

Based on aggregated 13F filings for Q4 2017.